Humacyte (HUMA) FCF Margin (2020 - 2026)
Humacyte (HUMA) posted quarterly FCF Margin of 5106.06% for Q1 2026, up 53127.0% year-over-year from N/an in Q1 2025, and up 8.71% quarter-over-quarter from 5593.36% in Q4 2025.
Humacyte (HUMA) FCF Margin (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported FCF Margin for 4 consecutive years, with 5106.06% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin rose 53127.0% year-over-year to 5106.06%; the TTM figure through Mar 2026 stood at 5060.22% (up 1449085.0% YoY), while the FY2025 annual figure was 5195.49%, changed N/A from the prior year.
- FCF Margin rose to 5106.06% in Q1 2026 per HUMA's latest filing, from 5593.36% in the prior quarter.
- Across five years, FCF Margin topped out at 3181.01% in Q3 2025 and bottomed at 8858.8% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.96 Bn | 132.11 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.20 Bn | 55.06 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 42.19 Bn | 37.09 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.43 Bn | 28.12 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 70.82% |
| 10 | Humacyte | 153.93 Mn | 153.93 Mn | -825,000.00 | -5,467.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5,467.98% |
| Mar 31, 2026 | -5,106.06% |
| Dec 31, 2025 | -5,593.36% |
| Sep 30, 2025 | -3,181.01% |
| Jun 30, 2025 | -8,858.80% |
| Mar 31, 2025 | -5,637.33% |
| Sep 30, 2021 | -12,646.06% |
| Sep 30, 2020 | -1.97% |